Dr. Daniel Flynn is a medicinal chemist and drug hunter with over 35 years of experience. For the past 20 years, Dr. Flynn was the Founder and Chief Scientific Officer at Deciphera Pharmaceuticals, a NASDAQ listed pharmaceutical company. While at Deciphera, he developed multiple drugs, including the on-market drug ripretinib (marketed as QINLOCK®), and a strong pipeline of kinase inhibitors. Prior to Deciphera, Dr. Flynn had senior scientific roles at Millennium Pharmaceuticals, Amgen, Monsanto/Searle and Warner Lambert Parke Davis. He has extensive expertise in medicinal chemistry, drug design, kinase inhibition, oncology and immunology. His research interests included oncology therapeutics, targeting tumor drivers, and also inhibitors of cancer cell adaptive response survival pathways. He is also Adjunct Professor, Department of Medicinal Chemistry, at the University of Kansas. Prior roles and honors also included Chair of the Medicinal Chemistry Division of the American Chemical Society, American Chemical Society Fellow, Founder of the Medicinal & Bioorganic Chemistry Foundation and the Steamboat Winter Conference on Medicinal & Bioorganic Chemistry. He is a past Senior Editor of Medicinal Research Reviews and has over 100 peer reviewed publications.